POINT

Condition

  • Stroke


Study Name

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial (IRB no. 36939)


Phase

Phase III


Summary

This study focuses on patients who have had a transient ischemic attack (TIA). The purpose of the study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel in reducing the risk of stroke, heart attacks and other complications. Clopidogrel is an antiplatelet drug, which works by helping to keep platelets (small blood cells needed for normal blood clotting) in the blood from forming harmful blood clots. Researchers will test the investigational use of clopidogrel with aspirin to reduce the risk of stroke or heart attack, compared to the use of aspirin alone.


Eligibility

Key Inclusion Criteria:

  • Neurological deficit attributed to focal brain ischemia and either:
    • High-risk transient ischemic attack or
    • Minor ischemic stroke
  • Ability to tolerate aspirin at a dose of 50-325 mg/day

Key Exclusion Criteria:

  • Younger than 18 years old
  • Transient ischemic attack symptoms limited to isolated numbness, isolated visual changes or isolated dizziness/vertigo
  • At risk for pregnancy

Please see additional list of inclusion and exclusion criteria.


Principal Investigator

Shlee Song, MD


Contact

(Peter) Chang Kim
Phone: 310-423-8041
Email: chang.kimx@cshs.org